{"id":933986,"date":"2026-02-04T10:07:23","date_gmt":"2026-02-04T15:07:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/"},"modified":"2026-02-04T10:07:23","modified_gmt":"2026-02-04T15:07:23","slug":"engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/","title":{"rendered":"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026"},"content":{"rendered":"

<\/p>\n

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026<\/b><\/p>\n

BOSTON & MONTREAL–(BUSINESS WIRE<\/a>)–
\nenGene Holdings Inc. (Nasdaq: ENGN or \u201cenGene\u201d), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET.<\/p>\n

\nA live webcast of the fireside chat can be accessed on the “Events and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at www.engene.com<\/a> and will be archived there for 90 days.<\/p>\n

About enGene<\/b><\/p>\n

\nenGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene\u2019s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene\u2019s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.<\/p>\n

\nTo learn more, please visit enGene.com<\/a> and follow us on LinkedIn<\/a>, X<\/a> and BlueSky<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260204527836\/en\/<\/a><\/span><\/p>\n

\nFor media contact:
\n
media@engene.com
\n<\/a><\/p>\n

For investor contact:
\n
investors@engene.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Canada Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Clinical Trials General Health Research Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 BOSTON & MONTREAL–(BUSINESS WIRE)– enGene Holdings Inc. (Nasdaq: ENGN or \u201cenGene\u201d), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live webcast of the fireside chat can be accessed on the “Events and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal … <\/p>\n

Continue reading “enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933986","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nenGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 BOSTON & MONTREAL–(BUSINESS WIRE)– enGene Holdings Inc. (Nasdaq: ENGN or \u201cenGene\u201d), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live webcast of the fireside chat can be accessed on the “Events and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal … Continue reading "enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T15:07:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026\",\"datePublished\":\"2026-02-04T15:07:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"},\"wordCount\":302,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\",\"name\":\"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-02-04T15:07:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/","og_locale":"en_US","og_type":"article","og_title":"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","og_description":"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 BOSTON & MONTREAL–(BUSINESS WIRE)– enGene Holdings Inc. (Nasdaq: ENGN or \u201cenGene\u201d), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live webcast of the fireside chat can be accessed on the “Events and Presentations\u201d page under the \u201cInvestors\u201d section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal … Continue reading \"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-04T15:07:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026","datePublished":"2026-02-04T15:07:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/"},"wordCount":302,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/","name":"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-02-04T15:07:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260204527836r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/engene-to-participate-in-the-guggenheim-emerging-outlook-biotech-summit-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933986"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933986\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}